6998 — Genor Biopharma Holdings Cashflow Statement
0.000.00%
- HK$586.03m
- -HK$656.47m
- 10
- 42
- 54
- 24
Annual cashflow statement for Genor Biopharma Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -524 | -3,036 | -866 | -732 | -677 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 111 | 2,414 | 129 | -6.54 | 159 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 262 | -215 | 52.4 | 108 | 16.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -111 | -787 | -624 | -578 | -425 |
Capital Expenditures | -27.9 | -98.3 | -71.4 | -13 | -1.03 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -12.7 | 0.049 | 17.1 | 0.015 | 7.02 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -40.7 | -98.2 | -54.3 | -12.9 | 5.99 |
Financing Cash Flow Items | -2.09 | -111 | -2.36 | -2.86 | -0.888 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 279 | 3,738 | 17.6 | -57.4 | -6.82 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 128 | 2,676 | -729 | -612 | -423 |